SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after Sanofi announced its acquisition for $15.50 per share, a move set to bolster Sanofi's adult immunization portfolio with Dynavax's hepatitis B vaccine and a shingles candidate. This news has sparked significant trading volume, with many long-term holders expressing disappointment over the acquisition price while also discussing the company's recent licensing deal for an oral COVID-19 vaccine program.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending after receiving a Complete Response Letter (CRL) from the FDA for its lead drug candidate, OLC, which cited manufacturing deficiencies at a third-party vendor, not issues with the drug's efficacy or safety. The community is weighing the short-term delay and potential for future dilution against OLC's strong clinical profile and the company's plan to resubmit for possible approval in the first half of the coming year. Many investors see this as a long-term opportunity, emphasizing that the drug's core benefits for dialysis patients remain intact despite regulatory setbacks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as the market digests news of new government contracts and its significant revenue backlog in the high-performance AI computing space. Community discussion is vibrant, with bulls pointing to strong demand and key industry backing, while others express caution regarding its substantial debt and recent insider share divestment.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT CRYPTO is trending amidst strong community discussion, largely fueled by its close association with Coinbase's #base platform and recent listing on Robinhood. Investors are actively debating its potential as a leading perpetual decentralized exchange, emphasizing its RWA trading features and high leverage offerings, despite some volatility and skepticism regarding past performance. The prevailing sentiment anticipates significant growth, positioning AVNT as a key player in the evolving crypto landscape.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

DRV is currently trending as the community actively discusses its significant collaboration with Synthetix to develop derivatives on Ethereum, signaling strong foundational growth. Traders are closely watching its 'slow and steady' performance and 'Onchain Matrix' tokenomics, anticipating further upside following recent consolidation and buyback discussions.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is trending amid discussions around its recent strategic financing and the U.S. Department of Energy taking a warrant, which bulls view as a significant derisking event to scale manufacturing for AI data centers and grid demands. While community sentiment is mixed on execution risk and dilution concerns, many anticipate substantial growth in the long-duration energy storage market. The company's unique non-lithium battery technology positions it to capitalize on increasing demand and government incentives, with focus on its path to consistent profitability.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to promising preliminary open-label Phase 3 trial results for its breast cancer immunotherapy, showing an 80% reduction in recurrence rates for a specific patient arm. This positive development, combined with high short interest, a soaring cost-to-borrow, and low share availability, is fueling community speculation about a significant short squeeze and potential buyout offers. Investors are also noting strong insider confidence and the company's strategic financial position, de-risking future prospects.

StoneCo Ltd. engages in the provision of financial technology solutions. It caters to merchants and partners that conduct electronic commerce across in-store, online, and mobile channels. The firm offers cloud-based technology platform, electronic payments, and automation of business processes at the point-of-sale. The company was founded by André Street de Aguiar in 2000 and is headquartered in George Town, Cayman Islands.

StoneCo Ltd - Ordinary Shares - Class A

StoneCo Ltd

StoneCo is trending following strong recent earnings beats, significant share buyback programs, and the strategic divestiture of its Linx software business to sharpen focus on the core MSMB segment. Community discussion highlights robust operational execution and impressive growth in areas like Pix adoption, alongside an attractive valuation. However, volatility and concerns about Brazil's political climate, including new fintech taxes, remain central to investor sentiment.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending due to its strategic pivot into AI-integrated network technologies, bolstered by a significant partnership with NVIDIA and substantial investments in US infrastructure for future connectivity. Despite these bullish developments and an upgraded financial outlook, the community is actively debating the stock's current price movements, with many anticipating a substantial revaluation as the company solidifies its position as a key player in 5G, 6G, and AI.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending as Google's acquisition of Intersect Power, a major customer, highlights solar's critical role in powering the rapidly expanding AI data center sector. The company's robust domestic manufacturing and favorable policy environment are driving significant analyst upgrades and community discussions about its undervalued status and potential for new highs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading on Wednesday. Stock traders bought 4,063 put options on the stock. This is an increase of...

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company

Wells Fargo & Company increased their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an "overweight" rating in a research report on Thursday...

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the stock. This represents an...

Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 10,830 shares of Xenon Pharmaceuticals stock in a transaction dated Monday, December 8th. The stock was sold at an...

Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 14,375 shares of the business's stock in a transaction dated Friday, December 5th. The shares were sold at an average...

Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE

Marshall Wace LLP increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 34.6% during the second quarter, according to the company in its most recent 13F filing with the...

New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE

New York State Common Retirement Fund raised its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 16.9% in the second quarter, according to its most recent 13F filing...

Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

Rhumbline Advisers grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 378,175.9% in the second quarter, according to its most recent disclosure with the Securities and...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned a consensus rating of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. One...

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week High - Here's What Happened

Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 1-Year High - Here's What Happened...

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Current Price	$44.84
Prev Close	$45.01
Open	$45.15
Dividend Yield	0.00%
50-Day Moving Average	$42.31
Beta	0.81
Avg. Volume	820,170.47
PE Ratio	-11.54

52-Week High	$46.60
52-Week Low	$26.74
Market Capitalization	$3.48B
EPS (Annual)	-$3.01
Price to Book	6.18
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

XENE
Xenon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XENE News

XENEXenon Pharmaceuticals Inc